Navigation Links
MIT's implantable device offers continuous cancer monitoring
Date:5/14/2009

CAMBRIDGE, Mass.--Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but only offer a snapshot of the tumor at a single moment in time.

Monitoring a tumor for weeks or months after the biopsy, tracking its growth and how it responds to treatment, would be much more valuable, says Michael Cima, MIT professor of materials science and engineering, who has developed the first implantable device that can do just that.

Cima and his colleagues recently reported that their device successfully tracked a tumor marker in mice for one month. The work is described in a paper published online in the journal Biosensors & Bioelectronics in April.

Such implants could one day provide up-to-the-minute information about what a tumor is doing whether it is growing or shrinking, how it's responding to treatment, and whether it has metastasized or is about to do so.

"What this does is basically take the lab and put it in the patient," said Cima, who is also an investigator at the David H. Koch Institute for Integrative Cancer Research at MIT.

The devices, which could be implanted at the time of biopsy, could also be tailored to monitor chemotherapy agents, allowing doctors to determine whether cancer drugs are reaching the tumors. They can also be designed to measure pH (acidity) or oxygen levels, which reveal tumor metabolism and how it is responding to therapy.

With current tools for detecting whether a tumor has spread, such as biopsy, by the time you have test results it's too late to prevent metastasis, said Cima.

"This is one of the tools we're going to need if we're going to turn cancer from a death sentence to a manageable disease," he said.

In the Biosensors & Bioelectronics study, human tumors were transplanted into the mice, and the researchers then used the implants to track levels of human chorionic gonadotropin, a hormone produced by human tumor cells.

The cylindrical, 5-millimeter implant contains magnetic nanoparticles coated with antibodies specific to the target molecules. Target molecules enter the implant through a semipermeable membrane, bind to the particles and cause them to clump together. That clumping can be detected by MRI (magnetic resonance imaging).

The device is made of a polymer called polyethylene, which is commonly used in orthopedic implants. The semipermeable membrane, which allows target molecules to enter but keeps the magnetic nanoparticles trapped inside, is made of polycarbonate, a compound used in many plastics.

Cima said he believes an implant to test for pH levels could be commercially available in a few years, followed by devices to test for complex chemicals such as hormones and drugs.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Gates Foundation Commits $280 Million for Research to Fight Global TB Epidemic
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
4. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
5. MacArthur commits $11 million to further UCSF work in maternal safety
6. Banco Popular Commits To Make A Difference Day 2007
7. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
8. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
9. Certain Cholesterol Drugs Show Their Limits
10. Gates Foundation Commits to Expansion of HIV Prevention in China
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 24, 2017 , ... Element Blue ™, a leading ... strategic partnership with Lucidworks , the company transforming the way people access ... for building powerful enterprise search applications. , Element Blue is a global team ...
(Date:1/24/2017)... ... January 24, 2017 , ... i2i Population Health, a national leader ... , “Cary’s broad financial background is an excellent fit for i2i,” ... and day-to-day financial operations skills we need to take the company to the next ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups ... of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and ... The entrepreneurs will showcase their businesses on February 6, 2017, at Under Armour’s ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future has ... Market for Wound Closure Device is growing rapidly and expected to continue ... ... at a CAGR of 5% from 2013 to 2019 and reaching a ... of the forecasted period, 2016-2022 Global Wound Closure Device Market ...
(Date:1/24/2017)... Nev. , Jan. 24, 2017  The ... that specializes in high-value orthopaedic implants, announced the ... today. The OIC Tibial Nail ... tibia. Strategically placed proximal and distal screw holes ... hole that allows dynamization.  The nail is available ...
(Date:1/24/2017)... 2017 Trifecta Clinical , a leading ... Rick Ward to Vice President of Commercial ... also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he was ... business development positions within the healthcare industry throughout his ...
Breaking Medicine Technology: